GlobeNewswire·Nov 10, 2026, 6:01 AM ET

MaxCyte Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Total Revenue Guidance

MXCT

MaxCyte reported total third quarter 2026 revenue of $10.2 million, comprising $8.2 million in core revenue and $2.0 million in SPL Program-related revenue.
Third quarter 2026 core revenue increased 27% year-over-year, while total revenue rose 49% compared to the same period in 2025.
The company raised its full-year 2026 total revenue guidance to at least $34.5 million, excluding the impact of the proposed Akron Bio acquisition.
MaxCyte announced a proposed acquisition of Akron Bio, a supplier of GMP-grade reagents, which is expected to nearly double the company's revenue base.
In July 2026, MaxCyte entered a strategic multi-platform technology license partnership with Genentech.
Third quarter 2026 net loss was $4.8 million, a significant improvement from the $12.4 million net loss recorded in the third quarter of 2025.
Operating expenses for the third quarter of 2026 were $14.5 million, down from $19.4 million in the prior year period.
Total cash, cash equivalents, and investments stood at $132.7 million as of September 30, 2026.
As of September 30, 2026, MaxCyte held 28 SPL agreements, including 13 programs currently in the clinic and one commercial program.
Full-year 2026 core revenue is projected to be approximately $28 million, with SPL Program-related revenue expected to be at least $6.5 million.
Assuming the Akron acquisition closes, MaxCyte anticipates ending 2026 with approximately $40.0 to $45.0 million in total cash after accounting for deal expenses and financing draws.
Third quarter 2026 gross margin was 83%, compared to 77% in the third quarter of 2025.
EBITDA for the third quarter of 2026 was a loss of $5.1 million, improved from a loss of $13.1 million in the same period last year.
MaxCyte will host a conference call on November 10, 2026, at 8:30 a.m. Eastern Time to discuss these results.

Company: MaxCyte, Inc
Keywords: Nasdaq:MXCT, MaxCyte, Inc